It has been estimated that 24 million Americans have diabetes, many of whom are Medicare beneficiaries. These individuals carefully monitor their blood glucose levels primarily through the use of in-home blood glucose testing kits. Although the test is relatively simple, the cumulative expense of providing glucose test strips and lancets to patients is ever increasing, both to the Medicare program and to uninsured individuals who must pay out-of-pocket for these testing supplies. This article discusses the diabetes durable medical equipment (DME) coverage under Part B Medicare, the establishment and role of DME Medicare administrative contractors, and national and local coverage requirements for diabetes DME suppliers. This article also discusses the federal government's ongoing concerns regarding the improper billing of diabetes testing supplies. To protect the Medicare Trust Fund, the federal government has contracted with multiple private entities to conduct reviews and audits of questionable Medicare claims. These private sector contractors have conducted unannounced site visits of DME supplier offices, interviewed patients and their families, placed suppliers on prepayment review, and conducted extensive postpayment audits of prior paid Medicare claims. In more egregious administrative cases, Medicare contractors have recommended that problematic providers and/or DME suppliers have their Medicare numbers suspended or, in some instances, revoked. More serious infractions can lead to civil or criminal liability. In the final part of this article, we will examine the future of enforcement efforts by law enforcement and Medicare contractors and the importance of understanding and complying with federal laws when ordering and supplying diabetes testing strips and lancets. and lancets to patients is ever increasing, both to the Medicare program and to uninsured individuals who must pay out of pocket for these supplies. This article discusses the current law enforcement landscape facing ordering physicians and durable medical equipment (DME) suppliers. It also examines a number of risk areas to be contemplated and avoided when ordering or supplying diabetes testing supplies to patients.
Introduction
It has been estimated that 24 million Americans have diabetes, many of whom are Medicare beneficiaries. These individuals carefully monitor their blood glucose levels primarily through the use of a test that measures the level of glucose in their blood. Although the test is relatively simple, the cumulative expense of providing glucose test strips
The secretary of HHS has been delegated overall authority in the administration and management of the Medicare and Medicaid programs. The secretary is authorized to issue guidance covering these programs but is not required to promulgate regulations or policies that "either by default rule or by specification, address every conceivable question" that may arise. 4 The secretary typically administers these programs through the direct issuance of formal and informal guidance. The secretary may also allow "specific applications of a rule [to] evolve" through the administrative appeals process. 4 Pursuant to 42 U.S.C.A. § 1395y(a)(1)(A), 5 Medicare covers items and services that are "reasonable and necessary for the diagnosis and treatment of illness or injury or to improve the functioning of a malformed body member." The secretary administers the Medicare program through an agency of HHS known as the Centers for Medicare and Medicaid Services (CMS). As set out in the HHS Quality Improvement Organization Manual, Chapter 1: Background and Responsibilities, § 1015, 6 the CMS's primary mission is to promote the timely delivery of appropriate, quality health care to beneficiaries, ensure that beneficiaries are aware of the services for which they are eligible, ensure that those services are accessible, and promote efficiency and quality in the programs under its administration.
Collectively, CMS-administered health insurance programs cover over 90 million Americans. 7 Approximately 4.5 million Medicare claims alone are processed each day. 8 Despite the extraordinary scope of the CMS's responsibilities, the agency's staff size is quite small, employing less than 5000 employees.
To accomplish its broad program obligations, the CMS has contracted with various private entities (which are primarily "for-profit" in nature) to process and pay Medicare claims filed by participating health care suppliers and providers. In some cases, these contractors also serve as the CMS's first-line representatives with participating providers and suppliers, interacting with them on an ongoing basis to address Medicare coverage questions, coding/billing concerns, and program participation issues that may arise. The CMS also relies on third-party contractors to perform medical reviews of provider claims, conduct periodic site visits, and initiate postpayment and prepayment audits of Medicare claims.
Establishment of Durable Medical Equipment Medicare Administrative Contractors
Pursuant to § 911 of the Medicare Prescription Drug Improvement and Modernization Act of 2003, the CMS has consolidated the handling and processing of Part A and Part B Medicare claims. Broadly speaking, Medicare Part A claims include inpatient hospital and skilled nursing facility claims. In contrast, Medicare Part B claims include physician services and most outpatient care claims. The CMS has combined these responsibilities to newly formed Medicare administrative contractors (MACs). Specialty MAC jurisdictions have been established to handle hospice and home health claims. Separate DME MACs have been set up in four jurisdictions to process claims filed by participating suppliers for covered DME, orthotic, prosthetic, and related items under Medicare Part B (see Figure 1 ). The term "DME" is defined as medical equipment that can withstand repeated use, is used primarily and customarily to serve a medical purpose, is generally not useful to a person in the absence of an illness or injury, and is appropriate for use in the home (42 CFR § 414.202). 9 The general basis for providing Medicare coverage for DME is found in § 1861(s)(6) of the Act, as amended by § 4062 of the Omnibus Budget Reconciliation Act of 1987.
Blood Glucose Test Strips and Lancets May Qualify for Coverage and Payment Under Medicare Part B
Under § § 1832(a)(1), 1861(s) (6) , and 1861(n) of the Social Security Act, home blood glucose test strips and lancets prescribed by a qualified physician to treat a diabetes patient may qualify for coverage and payment under Medicare Part B as long as the supplies are medically necessary and meet certain requirements specified by the CMS and DME MACs working on the CMS's behalf. These coverage and documentation requirements are intended to help ensure that test strips and lancets ordered for use by a Medicare beneficiary are, in fact, medically necessary. Unfortunately, many physicians and suppliers are either unaware of these detailed requirements or do not recognize the importance of properly maintaining supporting documentation. 10
National Coverage Determination and Local Coverage Determination Documentation Requirements
Although the CMS has not issued national coverage determination (NCD) guidance covering the medical necessity and usage of blood glucose test strips, it has addressed the program coverage of blood glucose monitors (see Medicare National Coverage Determinations Manual, Pub. No. 100-03, Chapter 1, § 40.2, effective June 19, 2006) . 11 As the NCD reflects, the CMS did not address the coverage and payment of medically necessary test strips or lancets. In an effort to address the medical necessity, coverage, documentation, and payment of these essential supplies, each of the four DME MACs have issued local coverage determination (LCD) guidance that addresses the various guidelines and rules to be followed by ordering physicians and suppliers of test strips and lancets. Jurisdictions A and B have issued LCD L11530. 12 Jurisdiction C has issued LCD L11520. 13 Finally, Jurisdiction D has issued LCD L196. 14
Local Coverage Determination Guidance Covering Blood-Glucose Test Strips and Lancets Has Been Issued and Specifically Addresses the Quantity of Test Strips and Lancets That Are Likely to Be Covered by Medicare
As a review of the LCD guidance cited earlier will show, each of the applicable LCDs specify the coverage, payment rules, and documentation requirements that must be met in order for test strips and lancets to qualify for coverage by Medicare. Importantly, all four LCDs limit coverage to 100 test strips and 100 lancets per Medicare patient per month if a Medicare beneficiary is insulin dependent. This quantity is intended to permit insulin-dependent beneficiaries to test their blood glucose levels up to three times per day. When a Medicare beneficiary is not insulin dependent, a contractor may only cover up to 100 test strips and 100 lancets every three months.
In certain instances, a Medicare beneficiary may need to assess their blood glucose levels more frequently than an LCD generally permits. Medicare permits more frequent testing as long as it is medically necessary and appropriate in light of a beneficiary's clinical profile and medical needs. The invoice submissions associated with these situations are sometimes referred to as "high utilization" claims. Medical documentation supporting the more frequent use of test strips must be maintained in a treating physician's records (and ultimately the supplier's records) in order to support a patient's high utilization of testing supplies.
There are a number of agencies tasked with the investigation and enforcement of the laws, rules, and regulations governing the coverage and payment of claims billed to Medicare by treating/ordering physicians and DME suppliers. Providers engaging in wrongdoing can be subject to administrative action, civil liability, and criminal prosecution. Moreover, depending on the facts and the culpability of a party, the government may choose to pursue one, two, or all three of these avenues of recourse. Each of these enforcement options are discussed here.
Administrative Actions
It is essential to keep in mind that the government has been accumulating utilization data related to both services and supplies since the passage of the Medicare and Medicaid programs in 1965. Today, "data mining" is an essential tool used by the CMS and its contractors to identify "outliers"-individuals or entities who bill differently than their peers. The CMS contractors exercise a wide degree of discretion and are expected to develop techniques and methodologies aimed at identifying health care providers and suppliers who may be engaging in improper treatment, coding, and/or billing practices. Through the application and assessment of historical billing and claims data, even the most ethical provider or supplier may appear to be an outlier and find themselves subjected to an unannounced visit, audit, or referral to law enforcement for further investigation.
The CMS and its contractors exercise a wide range of administrative enforcement authorities that may be used to examine, address, and/or deter potential and actual wrongdoing or fraud by a treating/ordering physician or DME supplier. In most regions of the country, the primary contractor auditing the Medicare claims of both nonhospital providers and suppliers are zone program integrity contractors (ZPICs). Possible administrative actions taken by ZPICs have included, but are not limited to the following:
• Unannounced Site Visits to Your Practice or Office. There are no statutory restrictions that prevent a ZPIC from "unexpectedly" visiting your practice or office and requesting to see documentation related to Medicare claims you have ordered or submitted to the program for payment. Moreover, as a participating physician or DME supplier, you have an obligation to cooperate with the contractor's review. Should ZPIC representatives show up at your medical practice or office, you will likely find that the ZPIC's auditors are knowledgeable, experienced, and professional in their dealings with you and your staff. When they do show up, they will likely already have a listing of the claims-related medical records and the specific records to be pulled from your files. The ZPICs have sometimes been known to show up with their own scanner or copier. This has led to problems for providers later on because they failed to request a copy of any documents taken by the contractor before it left. Should a ZPIC ask you to make copies, the contractor will often identify a handful of documents they intend to take with them at that time and ask that you forward additional supporting documentation by an agreed deadline. The ZPICs have requested both medical record and business-related documentation, such as contracts with medical directors and any leases for space. Notably, these business-related documents may be used to identify possible violations of the federal Anti-Kickback Statute or the civil False Claims Act.
• Unannounced Interviews of Diabetes Patients and Their Families. Since 2012, ZPIC auditors have been reported to have unexpectedly visited the homes of diabetes patients who are alleged to be high utilization users of blood glucose test strips and lancets. During these visits, ZPIC representatives (typically two people, one of whom is a registered nurse) have interviewed patients in an effort determine whether it was medically necessary for the patient to check his or her blood glucose levels more frequently than one would normally expect (in consideration of the patient's specific clinical profile). After interviewing a patient, a ZPIC would then conclude whether, in their professional opinion, the high utilization claims billed to Medicare were medically necessary. Unfavorable medical necessity determinations by a ZPIC can lead to a postpayment audit of prior paid claims, a recommendation to the CMS that a DME supplier should be suspended, or, in extreme cases, a recommendation to the CMS that a DME supplier's Medicare number should be revoked.
The HHS's Office of Inspector General (OIG) has expressed concern that providers and suppliers are improperly ordering and/or supplying Medicare beneficiaries with excessive blood glucose test strips and lancets. In mid 2012, the HHS OIG issued a report, Medicare Contractors Lacked Controls to Prevent Millions in Improper Payments for High Utilization Claims for Home Blood Glucose Test Strips and Lancets, A-09-11-02027 (June 2012), that examined whether the four DME contractors engaged by the CMS to process high-utilization claims for home blood glucose test strips and lancet supplies submitted by Part B suppliers properly handled these claims. 15 The supplies at issue were paid by the four DME contractors in calendar year 2007. The HHS OIG found that only 97 of the 400 (approximately 24%) paid high-utilization claims qualified for coverage and payment. The remaining 303 claims (76%) had one of more deficiencies which rendered it non-payable. The four major areas of deficiency are outlined in Table 1 . Table 1 .
Four Major Areas of Deficiency in "High-Utilization" Claims Examined
Four major areas of deficiency were noted. These included the following:
1 Over half of the claims reviewed (222 out of the 400 claims evaluated) were not supported by adequate documentation to justify the patient's need for these additional diabetes testing supplies. Specific documentation problems included the following:
• The medical documentation did not note the actual frequency of testing needed (thereby possibly supporting the need for additional testing supplies). • There was no documentation of the treating physician's clinical assessment of the patient's diabetes condition in the six months prior to the ordering of these supplies.
Based on these findings, the HHS OIG concluded that the four DME MACs improperly paid approximately $209 million to participating Medicare suppliers (out of a total of $275 million paid in fiscal year 2007). In light of the HHS OIG's findings, physicians and DME suppliers should reevaluate both their documentation and business practices to better ensure that high-utilization claims are only ordered and/or submitted in cases where the medical need for this frequency of testing is both fully documented and there is clear medical necessity for this frequency of testing. Moreover, refills must be fully supported by the record.
• Prepayment Reviews. With increasing frequency, both treating and ordering physicians and DME suppliers are finding themselves being placed on prepayment review by a ZPIC or DME MAC. When a physician or supplier is placed on prepayment review, the CMS contractor has essentially taken the position that an entity's claims should not be paid prior to being reviewed to ensure that the claims qualify for medical necessity, coverage, and payment. While this administrative remedy may sound like an imminently reasonable course of action to take, it has been our experience that few, if any, treating/ordering physicians or suppliers maintain a proverbial "rainy day" fund to pay employees and cover their expenses until the DME MAC determines whether or not specific claims should be paid. As a result, participating providers and suppliers placed on prepayment review or audit may be forced into bankruptcy because their cash flow has been disrupted.
Importantly, physicians and DME suppliers placed on prepayment review cannot challenge the action through an administrative appeals process. The only way to be removed from this status is to satisfy the CMS contractor that it is no longer necessary to review the supporting documentation of each claim before a payment determination is made.
• Postpayment Audits. The ZPICs around the country are actively conducting postpayment audits of blood glucose test suppliers and lancets submitted to Medicare for payment by DME suppliers. These audits typically involve the review of an alleged "statistically relevant sample" of the claims submitted and paid by Medicare over the course of one to three years. The CMS contractors then extrapolate from the sample to determine a projected overpayment. Providers challenging an overpayment may avail themselves of the administrative appeals process, but such an endeavor can take from 18 months to 2 years to reach the administrative law judge level of appeal.
• Suspension Actions. In cases where a ZPIC believes that a credible allegation of fraud exists, the contractor may recommend to the CMS that a participating provider or DME supplier should be placed on suspension. When this occurs, a physician provider or DME supplier may still provide services to Medicare beneficiaries. However, any monies that they are eligible to receive will be held by the MAC (in the case of a physician) or by a DME MAC (in the case of a DME supplier) until a postpayment audit can be conducted. As with a prepayment review, there is no administrative appeal process to challenge a suspension action. Although a provider or supplier may file a "rebuttal" statement, they are rarely granted. Suspension actions typically last a minimum of six months and are often in effect for a year or more. Any monies held by the CMS contractor will then be applied to any alleged overpayment. If a provider or supplier disagrees with the alleged overpayment, it can avail itself of the administrative appeals process. More often than not, a suspension action will lead to the bankruptcy and closure of a provider's or DME supplier's business. Few organizations with a significant Medicare patient load can remain in business for six months or more without receiving Medicare reimbursement for the services or supplies it has rendered to Medicare beneficiaries.
• Medicare Number Revocation. Revocation actions can arise in a number of ways. Two reasons frequently cited for revoking a provider's Medicare number are (1) failure to cooperate during a site visit and (2) failure to provide Medicare with a legitimate office address. As a participating provider or DME supplier, you have an obligation to cooperate with the ZPIC's review. Should you fail to cooperate, a ZPIC can recommend to the CMS that your Medicare number be revoked. This is a very real threat and should not be discounted. This becomes even more complicated if the ZPIC's representatives go beyond mere claims-related questions and appear to be seeking information that could subject you (in your individual capacity) to possible civil and/or criminal liability. While you must adhere with your obligations as a participating provider or supplier in the Medicare, you should still consult with your attorney to help ensure that your personal interests are properly protected. Similarly, you have an obligation to advise the government (and its contractors) if you move the location of your office. The ZPICs and other contractors conducting due diligence are routinely checking to ensure that participating providers and DME suppliers are operating legitimate, bona fide businesses. Should they travel to a listed address and find that you are not operating in that location, they will immediately notify the CMS so that your number can be revoked and the Medicare Trust Fund can be protected.
Civil Enforcement
While most remedial actions taken against a Medicare provider or supplier are administrative in nature, in certain instances, the government may determine that the conduct at issue warrants a more serious response. In such cases, the government may choose to pursue civil remedies against an offender. Potential civil remedies may take many forms, including but not limited to (1) injunctive relief; (2) an action against a provider or supplier for common law fraud, unjust enrichment, or payment by mistake; or (3) an action under the civil False Claims Act.
Civil False Claims Act (31 U.S.C. § § 3729-3733) 16 The False Claims Act is the primary civil enforcement tool utilized by federal prosecutors when pursuing allegations of civil health care fraud. Sometimes referred to as Lincoln's Law, the False Claims Act was first passed in 1863 in an effort to discourage and prevent war profiteering. Among its provisions were measures intended to encourage the disclosure of fraud. Under the qui tam (also commonly referred to as "whistleblower") provisions of the statute, a private person (often referred to as a "relator") can bring an False Claims Act lawsuit on behalf of, and in the name of, the United States. If a recovery is made, a relator may be eligible for a share of any monies recovered by the government. 17 The federal False Claims Act imposes civil penalties and damages against a violator under the circumstances in Table 2 .
Damages and Penalties under the False Claims Act
A person found to have violated this statute is liable for civil penalties in an amount between $5500 and not more than $11,000 per false claim, as well as up to three times the amount of damages sustained by the government.
Examples of Possible Civil Liability
As a careful review of recent enforcement efforts will show, the government exercises a wide degree of discretion when deciding whether to pursue allegations of wrongdoing as a mere overpayment, under the civil False Claims Act or, if the evidence is sufficiently compelling, under one of various criminal statutes. There are a number of factors considered by law enforcement when deciding whether to pursue a case through one, two, or even all three avenues of redress (this is commonly referred to as "parallel proceedings"). Actions that may lead to liability under the civil False Claims Act include, but are not limited to the following:
• Ordering and/or billing for DME supplies that are not medically necessary. Treating physicians ordering blood glucose testing supplies for patients must ensure that their orders are reflective of a patient's clinical needs and that any supplies ordered are medically necessary for the care and treatment of the patient. It is important to remember that, under the False Claims Act, if a person knowingly submits or causes a false claim to be submitted to the government for payment, the conduct may constitute a violation of the statute.
• Consignment closets could subject a provider to liability under the False Claims Act. In today's hyper-regulated health care environment, it is essential to keep in mind that any business relationship entered into between a treating physician and a DME supplier should be carefully vetted with the physician's health care attorney prior to moving forward. One common, potentially problematic practice involves the rental of "consignment closets" from a physician by DME suppliers. When a consignment closet is rented, a DME supplier is allowed to maintain DME supplies and devices on site, in a physician's office. If properly handled, a consignment closet can both greatly increase patient compliance and provide an opportunity for educating a patient regarding the use of a particular device or supplies before the patient leaves the physician's office. Typically, the DME supplier would handle billing for supplies distributed from the closet. Problems may arise in a number of different ways. One common concern is that patients may be pressured to buy a device or supplies at their physician's office rather than from an outside supplier. Depending on the facts, the business relationship between the physician and the DME supplier could conceivably run afoul of the False Claims Act, Stark laws, and/or the federal Anti-Kickback Statute. Under Stark, physicians are prohibited from making referrals of designated health services to an entity in which they have a financial interest. Under the Anti-Kickback Statute, it is illegal to knowingly and willfully offer, pay, solicit, or receive something of value to induce referrals of items or services covered by Medicare or other federal health benefits programs. 16 Sec. 3729. False Claims (a) Liability for Certain Acts-any person who:
(1) Knowingly presents, or causes to be presented, a false or fraudulent claim for payment or approval;
(2) Knowingly makes, uses, or causes to be made or used a false record or statement material to a false or fraudulent;
(3) Conspires to commit a violation of subparagraph (1), (2), (3), (4), or (5); (4) Has possession, custody, or control of property or money used, or to be used, by the government and knowingly delivers, or causes to be delivered, less than all of that money or property; (5) Is authorized to make or deliver a document certifying receipt of property used, or to be used, by the government and, intending to defraud the government, makes or delivers the receipt without completely knowing that the information on the receipt is true; (6) Knowingly buys, or receives as a pledge of an obligation or debt, public property from an officer or employee of the government, or a member of the armed forces, who lawfully may not sell or pledge the property; or (7) Knowingly makes, uses, or causes to be made or used a false record or statement material to an obligation to pay or transmit money or property to the government or knowingly conceals or knowingly and improperly avoids or decreases an obligation to pay or transmit money or property to the Government. . . is liable to the United States Government for treble damages and civil penalties. • Durable medical equipment suppliers who deliver and bill Medicare for supplies that are not supported by an appropriate medical order and/or may not be medically necessary may be liable under the False Claims Act. Durable medical equipment suppliers of blood glucose strips and lancets must exercise caution when filling an order and delivering supplies to Medicare beneficiaries. Does the current order for DME supplies cover the amount of blood glucose test strips that are being delivered and billed to Medicare? If the quantity of test strips would be considered a high-utilization claim, has the DME supplier obtained medical documentation from the treating physician that supports the medical necessity of this frequency of testing? It is imperative that treating physicians and DME suppliers alike regularly review and consider the utilization quantities set out in their applicable LCD. Durable medical equipment suppliers found to have shipped and billed high-utilization amounts of testing supplies to patients that are subsequently found to medically unnecessary may find themselves liable for the cost of these supplies, despite the fact that they were merely following the treating physician's order. Medicare auditors have held DME suppliers liable if the medical necessity of a high-utilization claim cannot be supported by the supplier when audited.
• Blood glucose test strips and lancets must be intended for sale and used in the United States. The domestic sale of test strips intended for sale abroad is prohibited and can lead to liability under the False Claims Act. Depending on the facts, it could conceivably also lead to criminal liability. Domestic manufacturers of blood glucose test strips intended for sale and use in this country take extraordinary steps to help ensure that their products fully comply with all laws, rules, and regulations enforced by the Food and Drug Administration. As set out here, a number of domestic manufacturers produce test strips both in the United States and abroad that are not intended for use or sale in this country. Durable medical equipment suppliers who import or otherwise divert these test strips for sale in the United States may run afoul of a wide number of criminal and/or civil statutes, including the False Claims Act.
Manufacturers take considerable care to ensure that blood glucose test strip package inserts are clear and easy to understand by patients. Manufacturers also annotate each package (typically containing 50 or 100 test strips) with important information needed to assist in calibrating a patient's test meter. Test strip boxes also reflect a "lot number" that is unique and can be used to determine where and when the strips were manufactured. This information is invaluable if a recall of defective or substandard test strips is needed. With this information, both the manufacturer and the government can quickly notify patients of potential quality problems.
Importantly, literally all testing supply manufacturers employ staff who serve as "secret shoppers." These individuals are responsible for visiting retail outlets where blood glucose test strips and lancets are sold. These secret shoppers purchase samples of the blood glucose test strip boxes for a variety of reasons. First, it lets the manufacturer know if the retail establishment is purchasing boxes of test strips directly from the manufacturer, from an authorized distributor, or from an unauthorized party. Small pharmacies and other retailers may seek to purchase extra boxes of low-priced test strips from unauthorized sellers on the Internet, from an online auction company, or from a retail distributor who is essentially selling the boxes on a wholesale basis to another retailer, in contravention of their contract with the manufacturer.
Blood glucose test strips purchased and imported from overseas for sale and use in the United States can often be bought on the "gray market" at a mere fraction of the cost of legitimately purchased domestic test strips. Moreover, test strips imported into the United States may not have been stored or transported in the proper manufacturer's recommended temperature and/or humidity-controlled environments. Additionally, as with imported pharmaceuticals, appearances may be deceiving. Boxes of test strips that appear to be those of a recognized manufacturer may be counterfeit cheap knock-offs, which are sold in an otherwise authentic-looking package.
In some cases, the seller or the retailer may have taken steps to hide the source of the test strips by altering the lot number or covering the manufacturer's statement that the strips are not intended for sale in this country. A worst case scenario would include situations where a seller or retailer has obliterated or attempted to change the expiration date printed on the box in an effort to sell expired test strips. Both the federal government and DME manufacturers Similarly, the illegal diversion of blood glucose test strips manufactured in the United States that are intended for sale and use overseas may also constitute an actionable civil violation. In many instances, these test strips are manufactured to the standards of the country where their sale is intended to take place. If these test strips are improperly diverted for sale in the United States, sellers may attempt to disguise that fact by attempting to remove the disclaimer placed on the package by the manufacturer.
Criminal Enforcement
In some instances, the government may determine that neither administrative nor civil enforcement is sufficient to address the egregious nature of a physician's or supplier's improper conduct. In such instances, the government may choose to pursue one or more criminal enforcement remedies at its disposal, including the following:
• Misbranding DME Supplies. In one case, 18 a nationally known manufacturer found that a batch of its test strips was defective and required recall. During this time period, the manufacturer also pulled boxes of test strips that appeared to have been damaged during shipment, along with those whose expiration dates were quickly approaching (or had already passed). The manufacturer subsequently contracted with an outside company to destroy these defective, damaged, and/or expired test strips. As the manufacturer would soon learn, the company failed to destroy the test strips. Instead, the company arranged to have these defective, damaged, and/or expired boxes of test strips sold on an Internet auction shopping Web site. It was later estimated that approximately 100 people bought the recalled test strips. One can only imagine the manufacturer's reaction when it learned that the company it had paid to destroy these testing supplies was instead selling them over the Internet. Consequently, the purchasers of the test strips were also surprised-none of them had been told that these strips had been pulled from sale by the manufacturer. In this particular case, the outside company that failed to destroy the damaged or expired test strips was criminally prosecuted for (1) introducing misbranded medical devices into interstate commerce, a violation of 21 U.S.C. § 331, and (2) wire fraud, a violation of 18 U.S.C. § 1343. 19
Future Enforcement Efforts
Each year, the HHS OIG issues an annual work plan for the upcoming fiscal year, which details specific areas of concern and provides insights into the areas the HHS OIG intends to investigate. As set out here, the HHS OIG's fiscal year 2013 work plan (issued on October 2, 2012) includes five specific areas related to diabetes testing supplies that will be addressed over the course of fiscal year 2013. 20 These five areas are outlined in Table 3 . Table 3 .
Areas of Concern Identified in the Department of Health and Human Services Office of Inspector General's 2013 Annual Work Plan
• Diabetes Testing Supplies: Supplier Compliance with Payment Requirements for Blood Glucose Test Strips and Lancets. The HHS OIG will be reviewing payments for home blood glucose test strips and lancets in an effort to determine whether payment was appropriate. As the 2013 Work Plan section further notes, the HHS OIG will be examining whether physicians and suppliers have complied with applicable requirements set out in the applicable LCD covering these supplies.
• Diabetes Testing Supplies: Effectiveness of System Edits to Prevent Inappropriate Payments for Blood-Glucose Test Strips and Lancets
to Lancets to Multiple Supplies. The HHS OIG will be reviewing the current claims edits employed by Medicare contractors to prevent inappropriate payments to multiple suppliers. The LCD guidelines include a requirement that suppliers may not dispense additional test strips to a beneficiary until the patient has nearly exhausted their current supply of test strips. • Diabetes Testing Supplies: Potential Questionable Billing for Test Strips in 2011. The HHS OIG will be reviewing Medicare claims data from 2011 in an effort to identify suppliers with inappropriate payments and/or questionable billing for diabetes test strips. The HHS OIG noted that recent investigations had found that diabetes test strips had been improperly and/or fraudulently billed to Medicare. • Diabetes Testing Supplies: Improper Supplier Billing for Test Strips in Competitive Bidding. The HHS OIG will be reviewing whether suppliers improperly billed Medicare for diabetes test strips in competitive bidding areas. The agency will also be examining whether suppliers engaged in inappropriate activities, such as waiving copayments, contacting beneficiaries, or sending unsolicited test strips to beneficiaries in 2010 or 2011. • Diabetes Testing Supplies: Supplier Compliance with Requirements for Non-Mail-Order Claims (New). The HHS OIG will be reviewing whether Part B payments for non-mail-order diabetes testing strips were made consistent with Medicare's requirements.
